TABLE 2.
One‐year rates and HRs for bleeding events in patients with atrial fibrillation and a history of gastrointestinal cancer according to initial prescription claim for a DOAC or VKA
| Outcome | Group | Bleeding events, n | Unweighted rate per 100 person‐years (95% CI) | Weighted rate per 100 person‐years (95% CI) | Weighted HR (95% CI) |
Standard DOAC dose Weighted HR (95% CI) |
|---|---|---|---|---|---|---|
| Any bleeding | DOAC | 128 | 10.36 (8.72, 12.33) | 10.53 (8.85, 12.62) | 0.95 (0.70, 1.29) | 1.11 (0.79, 1.56) |
| VKA | 57 | 10.17 (7.84, 13.18) | 11.02 (8.47, 14.58) | Ref | Ref | |
| Major bleeding | DOAC | 59 | 4.65 (3.60, 6.00) | 4.68 (3.63, 6.12) | 1.11 (0.69, 1.79) | 1.21 (0.72, 2.03) |
| VKA | 23 | 4.01 (2.66, 6.03) | 4.17 (2.77, 6.58) | Ref | Ref | |
| GI bleeding | DOAC | 66 | 5.21 (4.09, 6.63) | 5.36 (4.22, 6.90) | 0.95 (0.63, 1.45) | 1.18 (0.73, 1.89) |
| VKA | 31 | 5.41 (3.81, 7.70) | 5.62 (3.95, 8.26) | Ref | Ref | |
| Intracranial bleeding | DOAC | 7 | 0.54 (0.26, 1.13) | 0.50 (0.24, 1.20) | 0.32 (0.12, 0.86) | 0.23 (0.06, 0.96) |
| VKA | 7 | 1.20 (0.57, 2.52) | 1.57 (0.75, 3.86) | Ref | Ref |
Abbreviations: DOAC, direct oral anticoagulant; VKA, vitamin K antagonist.